Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Banu KARA |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment? / Hüseyin SANCAR BOZKURT in Autism - Open Access, 7-5 ([01/10/2017])
[article]
Titre : Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment? Type de document : Texte imprimé et/ou numérique Auteurs : Hüseyin SANCAR BOZKURT, Auteur ; Banu KARA, Auteur Article en page(s) : 3 p. Langues : Anglais (eng) Mots-clés : Mycosporin-like amino acids Bifidobacteria Neurological diseases Index. décimale : PER Périodiques Résumé : Gastrointestinal microbiota includes bacteria, archaea, viruses, fungi and other eukaryotes. The genus Bifidobacterium is considered the dominant once; it has an important role on immunologic, hormonal and metabolic homeostasis of the host. Recent studies demonstrated that the Mycosporin-like Amino Acids (MAAs) had prebiotic effects and they modulated host immunity by regulating the proliferation and differentiation of intestinal epithelial cells, macrophage and lymphocytes. Also MAAs modulate NF-?B and tryptophan metabolism. Modulation NF-?Band tryptophan metabolism induced a beneficial effect on central nervous cascade. The safety of Bifidobacterium species is known; although they do not produce MAAs, their presence is required for immunological response continuity of intestine. Thereby we hypothesize that if we could create Bifidobacteria species producing MAAs via genetic engineering; they might have stronger immuno-stimulatory properties and might be used as more potent pharmacological agents in neurological diseases secondary to impaired microbiota. En ligne : https://dx.doi.org/10.4172/2165-7890.1000219 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=410
in Autism - Open Access > 7-5 [01/10/2017] . - 3 p.[article] Can Fortified Bifidobacterium with Mycosporin-like Amino Acid be a New Insight for Neurological Disease' s Treatment? [Texte imprimé et/ou numérique] / Hüseyin SANCAR BOZKURT, Auteur ; Banu KARA, Auteur . - 3 p.
Langues : Anglais (eng)
in Autism - Open Access > 7-5 [01/10/2017] . - 3 p.
Mots-clés : Mycosporin-like amino acids Bifidobacteria Neurological diseases Index. décimale : PER Périodiques Résumé : Gastrointestinal microbiota includes bacteria, archaea, viruses, fungi and other eukaryotes. The genus Bifidobacterium is considered the dominant once; it has an important role on immunologic, hormonal and metabolic homeostasis of the host. Recent studies demonstrated that the Mycosporin-like Amino Acids (MAAs) had prebiotic effects and they modulated host immunity by regulating the proliferation and differentiation of intestinal epithelial cells, macrophage and lymphocytes. Also MAAs modulate NF-?B and tryptophan metabolism. Modulation NF-?Band tryptophan metabolism induced a beneficial effect on central nervous cascade. The safety of Bifidobacterium species is known; although they do not produce MAAs, their presence is required for immunological response continuity of intestine. Thereby we hypothesize that if we could create Bifidobacteria species producing MAAs via genetic engineering; they might have stronger immuno-stimulatory properties and might be used as more potent pharmacological agents in neurological diseases secondary to impaired microbiota. En ligne : https://dx.doi.org/10.4172/2165-7890.1000219 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=410